Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression

doi:10.4251/wjgo.v13.i9.980

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5625)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

347

WORD

148

HTML

2960

Figures (1-3)

239

Sum=3694

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

397

Download

579

Sum=976

Publishing Process of This Article

Item

Count

Browse

397

Download

558

Sum=955

Sep 15, 2021 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Sep 15, 2021; 13(9): 980-994
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.980

Full Size Figure Download Figure

Figure 3 Schematic model of the effect of TNIIIA2 on colitis-associated colorectal cancer onset. Peptide TNIIIA2 stimulates fibroblasts to secrete humoral factors, promoting anchorage-dependent and -independent growth in preneoplastic cells. Created with BioRender.com. CAC: Colitis-associated colorectal cancer.

Citation: Fujita M, Suzuki H, Fukai F. Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression. World J Gastrointest Oncol 2021; 13(9): 980-994
URL: https://www.wjgnet.com/1948-5204/full/v13/i9/980.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i9.980